Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03340259
Other study ID # MICROENTE_01
Secondary ID
Status Recruiting
Phase N/A
First received November 8, 2017
Last updated November 8, 2017
Start date June 21, 2017
Est. completion date June 2020

Study information

Verified date July 2017
Source Universidade do Porto
Contact Luís Pereira-da-Silva, MD, PhD
Phone +351 917235528
Email l.pereira.silva@nms.unl.pt
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The human microbiota, a collection of microorganisms mostly settled in the gastrointestinal tract, plays a major role in the maintenance of the hosts' health and in development of disease as well. Exposure to different conditions early in life contributes to distinct "pioneer" bacterial communities, which shape the newborn infants' development and influence their later physiological, immunological and neurological homeostasis. Newborn infants with congenital malformations of the gastrointestinal tract (CMGIT), necrotizing enterocolitis (NEC), and spontaneous intestinal perforation (SIP) commonly require abdominal surgery and enterostomy. While intestinal microbiota has been extensively studied in infants with anatomically uninterrupted intestine, the knowledge of longitudinal intestinal colonization in this population is scarce.

This is an exploratory, observational, and longitudinal prospective study, primarily aimed to determine longitudinally the colonization of the proximal remnant intestine, in newborn infants with enterostomy after surgery (three weeks) for CMGIT, NEC and SIP. The secondary aim is to explore the associations of the colonization with the mode of delivery, gestational age, postnatal age, duration of fasting, type of enteric feeding, antimicrobial therapy, H2-receptor antagonist therapy, and length of proximal remnant intestine.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date June 2020
Est. primary completion date June 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion criteria: newborn infants with enterostomy after surgery for CMGIT, NEC or SIP, consecutively admitted

Exclusion criteria: newborn infants with diagnosed inborn errors of metabolism, those whose parents or legal guardians will not consent to participate or withdrawn the consent, and those who had not complete 21 days of follow-up.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Exposure(s) of interest: enterostomy
Newborn infants with congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation commonly require surgery and enterostomy. In these infants samples of the enterostomy effluent will be collected and DNA extracted for microbiota identification.

Locations

Country Name City State
Portugal Neonatal Intensive Care Unit, Hospital Dona Estefânia, Centro Hospitalar de Lisboa Central Lisbon

Sponsors (4)

Lead Sponsor Collaborator
Universidade do Porto CINTESIS - Center for Health Technology and Services Research, Porto, Hospital Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisboa, NOVA Medical School, Universidade Nova de Lisboa

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pattern of postsurgical intestinal microbiota colonization specific to each underlying condition Longitudinal postsurgical microbiota colonization of the proximal remnant intestine, specific to each underlying condition The first sample will be collected as close as possible after placement of ostomy bag. From the first collection, new samples will be collected every 3 days, until the 21st day after surgery
Secondary Associations of types of microorganism identified with below defined clinical variables Associations of microbiota colonization with the mode of delivery, gestational age, postnatal age, duration of fasting, type of enteric feeding, antimicrobial therapy, H2-receptor antagonist therapy, and length of proximal remnant intestine. The aforementioned clinical variables will be collected daily and the enterostomy effluent collected from the first placement of ostomy bag and every 3 days thereafter up to 21 days after surgery